Abstract
Objective: Acute exposure to hypoxia generally increase the ventilation. However, some of COVID-19 patients who suffer from
pneumonia are characterized by hypoxic ventilatory depression with loss of dyspnea which is called as happy hypoxia. This
report describes the background and the clinical issues of happy hypoxia.
Methods: The mechanisms to increase ventilation and dyspnea under hypoxia are explained. Further, clinical issues and
characteristics in COVID-19 are reviewed.
Results: Genetic factors are definitely concerned with chemosensitivity to hypoxia. Further disease factors including COVID-19 infection could influence the attenuation of the chemosensitivity. This can be attributed to either ventilatory depression due
to the modulation of metabolic substrate, adenosine in the brain, or autonomic neuropathy including the dysfunction of the
carotid body.
Conclusions: COVID-19 patients must be carefully treated and/or monitored to avoid hypoxic ventilator depression. The clinical
application of aminophylline will be an issue to be considered.